These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 27034721)
1. An update on the use of transdermal oxybutynin in the management of overactive bladder disorder. Cohn JA; Brown ET; Reynolds WS; Kaufman MR; Milam DF; Dmochowski RR Ther Adv Urol; 2016 Apr; 8(2):83-90. PubMed ID: 27034721 [TBL] [Abstract][Full Text] [Related]
2. Development of oxybutynin chloride topical gel for overactive bladder. Lucente VR; Staskin DR; De E Open Access J Urol; 2011 Apr; 3():35-42. PubMed ID: 24198634 [TBL] [Abstract][Full Text] [Related]
3. Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder. Wagg A Res Rep Urol; 2012; 4():57-64. PubMed ID: 24199182 [TBL] [Abstract][Full Text] [Related]
6. Which anticholinergic drug for overactive bladder symptoms in adults. Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963 [TBL] [Abstract][Full Text] [Related]
7. The evolution of transdermal therapy for overactive bladder. Sand PK Curr Urol Rep; 2009 Sep; 10(5):338-41. PubMed ID: 19709479 [TBL] [Abstract][Full Text] [Related]
8. Oxybutynin topical and transdermal formulations: an update. Staskin DR; Salvatore S Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610 [TBL] [Abstract][Full Text] [Related]
9. Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin. Gamble T; Sand P Patient Prefer Adherence; 2008 Feb; 2():349-56. PubMed ID: 19920982 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial. Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H; Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662 [TBL] [Abstract][Full Text] [Related]
11. Transdermal oxybutynin for overactive bladder. Davila GW; Starkman JS; Dmochowski RR Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381 [TBL] [Abstract][Full Text] [Related]
12. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo. Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H; Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779 [TBL] [Abstract][Full Text] [Related]
13. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Staskin DR; Robinson D Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278 [TBL] [Abstract][Full Text] [Related]
14. Transdermal oxybutynin: a new treatment for overactive bladder. Davila GW Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930 [TBL] [Abstract][Full Text] [Related]
15. Transdermal drug delivery treatment for overactive bladder. Dmochowski RR; Starkman JS; Davila GW Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319 [TBL] [Abstract][Full Text] [Related]
16. Transdermal oxybutynin: for overactive bladder. Bang LM; Easthope SE; Perry CM Drugs Aging; 2003; 20(11):857-64. PubMed ID: 12964892 [TBL] [Abstract][Full Text] [Related]
17. Oxybutynin gel for the treatment of overactive bladder. Gomelsky A; Dmochowski RR Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010 [TBL] [Abstract][Full Text] [Related]